Drug profile · INN
raxibacumab
RAXIBACUMAB
raxibacumab (RAXIBACUMAB) is a protective antigen binding agent. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — raxibacumab
- US status
- approved
- Class
- —
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
raxibacumab (RAXIBACUMAB) is a protective antigen binding agent. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Protective antigen binding agent
Primary target: Protective antigen
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is raxibacumab?
raxibacumab (RAXIBACUMAB) is a protective antigen binding agent. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for raxibacumab?
RAXIBACUMAB is a marketed brand name for raxibacumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of raxibacumab?
raxibacumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.